Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
N4 Pharma ( (GB:N4P) ) just unveiled an update.
N4 Pharma plc announced an upcoming investor presentation and Q&A session to be held on February 4, 2025, highlighting its lead programme, N4 101, an orally delivered RNA therapeutic targeting inflammatory bowel disease. This event is open to current and potential shareholders, providing an opportunity to gain insights into the company’s developments and strategic direction.
More about N4 Pharma
N4 Pharma plc is a biotechnology company focused on developing Nuvec®, its proprietary gene delivery system aimed at advancing therapies for cancer and other diseases.
YTD Price Performance: 23.81%
Average Trading Volume: 1,879,492
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £7.06M
For an in-depth examination of N4P stock, go to TipRanks’ Stock Analysis page.
